Symbols / DBVT
DBVT Chart
About
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.28B |
| Enterprise Value | 3.70B | Income | -125.13M | Sales | 5.50M |
| Book/sh | 0.39 | Cash/sh | 0.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | 117 | IPO | — |
| P/E | — | Forward P/E | -42.52 | PEG | — |
| P/S | 232.14 | P/B | 60.21 | P/C | — |
| EV/EBITDA | — | EV/Sales | 672.57 | Quick Ratio | 1.73 |
| Current Ratio | 1.80 | Debt/Eq | 14.55 | LT Debt/Eq | — |
| EPS (ttm) | -5.20 | EPS next Y | -0.55 | EPS Growth | — |
| Revenue Growth | 158.80% | Earnings | 2026-03-23 | ROA | -77.29% |
| ROE | -234.14% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -12.36% | Profit Margin | 0.00% | Shs Outstand | 54.96M |
| Shs Float | 136.68M | Short Float | 2.65% | Short Ratio | 2.68 |
| Short Interest | — | 52W High | 26.18 | 52W Low | 3.82 |
| Beta | -0.19 | Avg Volume | 527.51K | Volume | 12.98K |
| Target Price | $39.99 | Recom | Buy | Prev Close | $22.27 |
| Price | $23.24 | Change | 4.36% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$39.95
Mean price target
2. Current target
$22.27
Latest analyst target
3. DCF / Fair value
$-16.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.27
Low
$8.15
High
$50.59
Mean
$39.95
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-12-17 | main | Cantor Fitzgerald | Overweight → Overweight | $48 |
| 2025-12-17 | main | Citizens | Market Outperform → Market Outperform | $45 |
| 2025-12-17 | main | Guggenheim | Buy → Buy | $51 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-12-15 | init | Cantor Fitzgerald | — → Overweight | $42 |
| 2025-12-03 | init | Guggenheim | — → Buy | $35 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-06-26 | reit | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2025-05-27 | main | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2025-05-05 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-01 | main | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-03-04 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $10 |
| 2025-01-10 | reit | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2024-12-10 | reit | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2024-10-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-07-31 | main | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2024-05-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-02-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- Peanut allergy patch data in young children to get spotlight at AAAAI 2026 - Stock Titan ue, 10 Feb 2026 08
- (DBVT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Fri, 20 Feb 2026 20
- $DBVT stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Mon, 08 Dec 2025 08
- DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally (NASDAQ:DBVT) - Seeking Alpha hu, 11 Dec 2025 08
- DBV Technologies stock soars after positive Phase 3 trial results - Investing.com ue, 16 Dec 2025 08
- DBVT Stock Rockets on Positive Peanut Allergy Patch Trial - RagingBull Wed, 17 Dec 2025 08
- DBV Technologies Stock (DBVT) Soars as Clinical Trial Results Trigger Analyst Price Target Increases - TipRanks Wed, 17 Dec 2025 08
- DBVT Stock Surges Over 78% in After-Hours Trading - GuruFocus ue, 16 Dec 2025 08
- Why DBV Technologies S.A. (DBVT) is Surging in 2025 - Yahoo Finance Wed, 30 Apr 2025 07
- DBVT Soars On Positive Phase 3 Trial Of VIASKIN Peanut Patch - Nasdaq Wed, 17 Dec 2025 08
- DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing - Stocktwits ue, 16 Dec 2025 23
- $DBVT stock is down 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 05 Jan 2026 08
- DBV Technologies posts peanut allergy trial win (DBVT:NASDAQ) - Seeking Alpha Wed, 17 Dec 2025 08
- DBVT Stock: HC Wainwright & Co. Raises Price Target to $35.00 | - GuruFocus Mon, 15 Dec 2025 08
- Liquidity Mapping Around (DBVT) Price Events - Stock Traders Daily Sun, 18 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 534 | 12261 | — | Sale at price 22.96 per share. | MOHIDEEN PHARIS | Officer | — | 2026-01-29 00:00:00 | D |
| 1 | 464 | 4547 | — | Sale at price 9.80 per share. | MOHIDEEN PHARIS | Officer | — | 2025-07-29 00:00:00 | D |
| 2 | 907 | 503 | — | Sale at price 0.53 - 0.57 per share. | MOHIDEEN PHARIS | Officer | — | 2024-11-25 00:00:00 | D |
| 3 | 1785 | 1749 | — | Sale at price 0.98 per share. | MOHIDEEN PHARIS | Officer | — | 2024-07-29 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 3.59K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -109.05M | -67.27M | -83.47M | -87.24M |
| TotalUnusualItems | 0.00 | 920.00K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 920.00K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -113.92M | -72.73M | -96.27M | -97.81M |
| ReconciledDepreciation | -925.00K | -14.00M | 13.16M | 8.38M |
| EBITDA | -109.05M | -67.27M | -83.47M | -86.32M |
| EBIT | -116.59M | -76.43M | -96.63M | -99.53M |
| NetInterestIncome | 2.73M | 3.71M | 427.00K | 425.00K |
| NormalizedIncome | -113.92M | -72.73M | -96.27M | -98.73M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -113.92M | -72.73M | -96.27M | -97.81M |
| TotalExpenses | 116.59M | 76.43M | 96.63M | 99.53M |
| TotalOperatingIncomeAsReported | -116.59M | -76.43M | -96.63M | -98.61M |
| DilutedAverageShares | 19.47M | 19.02M | 15.53M | 10.99M |
| BasicAverageShares | 19.47M | 19.02M | 15.53M | 10.99M |
| DilutedEPS | -5.85 | -3.80 | -6.20 | -8.90 |
| BasicEPS | -5.85 | -3.80 | -6.20 | -8.90 |
| DilutedNIAvailtoComStockholders | -113.92M | -72.73M | -96.27M | -97.81M |
| NetIncomeCommonStockholders | -113.92M | -72.73M | -96.27M | -97.81M |
| NetIncome | -113.92M | -72.73M | -96.27M | -97.81M |
| NetIncomeIncludingNoncontrollingInterests | -113.92M | -72.73M | -96.27M | -97.81M |
| NetIncomeContinuousOperations | -113.92M | -72.73M | -96.27M | -97.81M |
| TaxProvision | 55.00K | 7.00K | 70.00K | -381.00K |
| PretaxIncome | -113.86M | -72.72M | -96.20M | -98.19M |
| OtherIncomeExpense | 920.00K | |||
| SpecialIncomeCharges | 0.00 | 920.00K | ||
| RestructuringAndMergernAcquisition | 0.00 | -920.00K | ||
| NetNonOperatingInterestIncomeExpense | 2.73M | 3.71M | 427.00K | 425.00K |
| TotalOtherFinanceCost | -2.73M | -3.71M | -427.00K | -425.00K |
| OperatingIncome | -116.59M | -76.43M | -96.63M | -99.53M |
| OperatingExpense | 116.59M | 76.43M | 96.63M | 99.53M |
| OtherOperatingExpenses | -5.00K | -6.96M | 874.00K | 1.80M |
| OtherTaxes | -4.15M | -8.77M | -5.72M | -7.50M |
| DepreciationAmortizationDepletionIncomeStatement | 7.54M | 9.16M | 8.37M | 13.22M |
| DepreciationAndAmortizationInIncomeStatement | 7.54M | 9.16M | 8.37M | 13.22M |
| ResearchAndDevelopment | 89.34M | 60.22M | 75.54M | 70.34M |
| SellingGeneralAndAdministration | 23.85M | 22.78M | 17.56M | 21.69M |
| SellingAndMarketingExpense | 4.39M | |||
| GeneralAndAdministrativeExpense | 23.85M | 22.78M | 17.56M | 21.69M |
| OtherGandA | 11.82M | 10.43M | 6.64M | 10.45M |
| SalariesAndWages | 12.03M | 12.34M | 10.92M | 11.24M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 266.87K | 222.99K | 149.79K | 153.63K |
| OrdinarySharesNumber | 102.58M | 96.21M | 93.99M | 54.94M |
| ShareIssued | 102.85M | 96.43M | 94.14M | 55.10M |
| TotalDebt | 7.80M | 6.55M | 4.15M | 11.98M |
| TangibleBookValue | 27.35M | 140.13M | 194.44M | 99.25M |
| InvestedCapital | 28.23M | 141.07M | 195.59M | 101.11M |
| WorkingCapital | 13.25M | 121.58M | 193.55M | 82.99M |
| NetTangibleAssets | 27.35M | 140.13M | 194.44M | 99.25M |
| CapitalLeaseObligations | 6.95M | 5.67M | 3.02M | 10.15M |
| CommonStockEquity | 27.39M | 140.19M | 194.45M | 99.28M |
| TotalCapitalization | 27.39M | 140.19M | 194.45M | 99.28M |
| TotalEquityGrossMinorityInterest | 27.39M | 140.19M | 194.45M | 99.27M |
| StockholdersEquity | 27.39M | 140.19M | 194.45M | 99.28M |
| GainsLossesNotAffectingRetainedEarnings | -12.19M | -8.13M | -13.80M | -5.62M |
| OtherEquityAdjustments | 905.00K | 742.00K | 781.00K | 519.00K |
| ForeignCurrencyTranslationAdjustments | -13.10M | -8.87M | -14.58M | -6.14M |
| TreasuryStock | 1.31M | 1.26M | 1.11M | 1.23M |
| RetainedEarnings | -286.38M | -238.86M | -259.58M | -258.53M |
| AdditionalPaidInCapital | 315.61M | 377.47M | 458.22M | 358.12M |
| CapitalStock | 11.65M | 10.97M | 10.72M | 6.54M |
| CommonStock | 11.65M | 10.97M | 10.72M | 6.54M |
| TotalLiabilitiesNetMinorityInterest | 38.27M | 42.80M | 52.06M | 47.45M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.13M | 5.46M | 22.54M | 16.05M |
| OtherNonCurrentLiabilities | 838.00K | 934.00K | 21.42M | 8.90M |
| LongTermDebtAndCapitalLeaseObligation | 6.30M | 4.53M | 1.13M | 7.15M |
| LongTermCapitalLeaseObligation | 6.30M | 4.53M | 1.13M | 7.15M |
| CurrentLiabilities | 31.14M | 37.34M | 29.52M | 31.40M |
| OtherCurrentLiabilities | 7.42M | 11.79M | 9.82M | 10.80M |
| CurrentDeferredLiabilities | 0.00 | 2.14M | 4.15M | |
| CurrentDeferredRevenue | 0.00 | 2.14M | 4.15M | |
| CurrentDebtAndCapitalLeaseObligation | 1.50M | 2.03M | 3.02M | 4.84M |
| CurrentCapitalLeaseObligation | 654.00K | 1.14M | 1.89M | 3.00M |
| CurrentDebt | 846.00K | 883.00K | 1.13M | 1.83M |
| OtherCurrentBorrowings | 846.00K | 883.00K | 1.13M | 1.83M |
| PayablesAndAccruedExpenses | 22.22M | 23.52M | 14.54M | 11.61M |
| Payables | 22.22M | 23.52M | 14.54M | 11.61M |
| TotalTaxPayable | 188.00K | 223.00K | 69.00K | 182.00K |
| AccountsPayable | 22.03M | 23.30M | 14.47M | 11.43M |
| TotalAssets | 65.66M | 182.99M | 246.52M | 146.72M |
| TotalNonCurrentAssets | 21.27M | 24.07M | 23.44M | 32.34M |
| OtherNonCurrentAssets | 6.08M | 3.74M | 3.97M | |
| NonCurrentPrepaidAssets | 1.77M | 2.67M | ||
| NonCurrentAccountsReceivable | 111.00K | 312.00K | 199.00K | |
| InvestmentsAndAdvances | 4.31M | 1.77M | 2.67M | |
| InvestmentinFinancialAssets | 4.31M | 1.77M | 2.67M | |
| AvailableForSaleSecurities | 4.31M | 1.77M | 2.67M | |
| GoodwillAndOtherIntangibleAssets | 40.00K | 58.00K | 10.00K | 22.00K |
| NetPPE | 16.81M | 17.93M | 17.61M | 25.48M |
| AccumulatedDepreciation | -17.53M | -18.95M | -14.79M | -13.80M |
| GrossPPE | 34.34M | 36.88M | 32.40M | 39.28M |
| ConstructionInProgress | 1.19M | 1.46M | 4.47M | 4.39M |
| OtherProperties | 30.05M | 30.89M | 22.97M | 28.77M |
| MachineryFurnitureEquipment | 3.10M | 4.53M | 1.74M | 2.16M |
| BuildingsAndImprovements | 3.33M | 3.21M | 3.96M | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 44.39M | 158.91M | 223.07M | 114.39M |
| OtherCurrentAssets | -1.00K | 1.00K | 1.00K | |
| PrepaidAssets | 1.54M | 2.10M | 2.68M | 4.15M |
| Receivables | 10.39M | 15.45M | 11.20M | 32.94M |
| OtherReceivables | 1.96M | 1.35M | 1.50M | 1.28M |
| TaxesReceivable | 8.43M | 14.09M | 9.70M | 31.65M |
| AccountsReceivable | 0.00 | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 32.46M | 141.37M | 209.19M | 77.30M |
| CashAndCashEquivalents | 32.46M | 141.37M | 209.19M | 77.30M |
| CashEquivalents | 0.00 | 130.84M | 179.09M | 45.87M |
| CashFinancial | 32.46M | 10.53M | 30.10M | 31.43M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -106.81M | -80.33M | -56.42M | -109.16M |
| RepurchaseOfCapitalStock | -47.00K | -154.00K | ||
| IssuanceOfCapitalStock | 634.00K | 6.92M | 194.59M | 978.00K |
| CapitalExpenditure | -2.34M | -677.00K | -754.00K | -918.00K |
| EndCashPosition | 32.46M | 141.37M | 209.19M | 77.30M |
| BeginningCashPosition | 141.37M | 209.19M | 77.30M | 196.35M |
| EffectOfExchangeRateChanges | -4.27M | 5.87M | -6.46M | -10.65M |
| ChangesInCash | -104.64M | -73.69M | 138.35M | -108.40M |
| FinancingCashFlow | 587.00K | 6.77M | 194.12M | 274.00K |
| CashFlowFromContinuingFinancingActivities | 587.00K | 6.77M | 194.12M | 274.00K |
| NetOtherFinancingCharges | -474.00K | -704.00K | ||
| NetCommonStockIssuance | 587.00K | 6.77M | 194.59M | 978.00K |
| CommonStockPayments | -47.00K | -154.00K | ||
| CommonStockIssuance | 634.00K | 6.92M | 194.59M | 978.00K |
| InvestingCashFlow | -757.00K | -808.00K | -100.00K | -433.00K |
| CashFlowFromContinuingInvestingActivities | -757.00K | -808.00K | -99.00K | -433.00K |
| NetOtherInvestingChanges | 1.58M | -131.00K | -1.00K | |
| NetInvestmentPurchaseAndSale | -131.00K | 647.00K | -119.00K | |
| SaleOfInvestment | 154.00K | 770.00K | 0.00 | |
| PurchaseOfInvestment | -285.00K | -123.00K | -119.00K | |
| NetIntangiblesPurchaseAndSale | -3.00K | 0.00 | 0.00 | -8.00K |
| PurchaseOfIntangibles | -3.00K | 0.00 | 0.00 | -8.00K |
| NetPPEPurchaseAndSale | -2.34M | -677.00K | -746.00K | -306.00K |
| SaleOfPPE | 0.00 | 8.00K | 604.00K | |
| PurchaseOfPPE | -2.34M | -677.00K | -754.00K | -910.00K |
| OperatingCashFlow | -104.47M | -79.65M | -55.67M | -108.24M |
| CashFlowFromContinuingOperatingActivities | -104.47M | -79.65M | -55.67M | -108.24M |
| ChangeInWorkingCapital | 5.75M | 953.00K | 22.32M | -22.77M |
| ChangeInOtherWorkingCapital | 485.00K | 1.66M | -2.25M | -1.19M |
| ChangeInOtherCurrentLiabilities | 366.00K | -5.33M | 152.00K | -7.60M |
| ChangeInOtherCurrentAssets | 4.63M | -3.79M | 20.96M | -8.58M |
| ChangeInPayablesAndAccruedExpense | 272.00K | 8.42M | 3.46M | -7.56M |
| ChangeInPayable | 272.00K | 8.42M | 3.46M | -7.56M |
| ChangeInAccountPayable | 272.00K | 8.42M | 3.46M | -7.56M |
| ChangeInInventory | 0.00 | 0.00 | 0.00 | |
| ChangeInReceivables | 0.00 | 0.00 | 2.15M | |
| ChangesInAccountReceivables | 0.00 | 0.00 | 2.15M | |
| OtherNonCashItems | -3.00K | 23.00K | -5.00K | 656.00K |
| StockBasedCompensation | 4.62M | 6.02M | 5.03M | 3.12M |
| DepreciationAmortizationDepletion | -925.00K | -14.00M | 13.16M | 8.38M |
| DepreciationAndAmortization | -925.00K | -14.00M | 13.16M | 8.38M |
| Depreciation | -925.00K | -14.00M | 13.16M | 8.38M |
| OperatingGainsLosses | 76.00K | 105.00K | 184.00K | |
| PensionAndEmployeeBenefitExpense | 0.00 | 76.00K | 105.00K | 184.00K |
| NetIncomeFromContinuingOperations | -113.92M | -72.73M | -96.27M | -97.81M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DBVT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|